Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aldeyra Therapeutics Inc

ALDX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.56

▲ +8.33%

Market Cap $94.11M · Vol 209.96K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$94.11M

Micro Cap

Div Yield

N/A

EPS Growth

+41.07%

YoY

RSI (14)

47.42

Momentum

Beta

1.19

vs Market

52W High

$6.17

74.72% below

52W Low

$1.08

45.12% above

Volume

209.96K

Avg 332.77K

P/B

7.04

Price-to-book

ROE

N/A

Return on equity

Free Float

96.40%

Public shares

Shariah Compliance8 STANDARDS

✗ Aldeyra Therapeutics Inc (ALDX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.65%

-19.17%

-6.02%

-70.45%

YTD

-69.88%

-70.57%

-80.15%

-83.21%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-33,846,660.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-38.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.04
P/FCF	N/A
EPS Growth	+41.07%
Outstanding Shares	60.33M

Technical Indicators

50-Day SMA	$1.79
200-Day SMA	$3.28
RSI (14)	47.42
Beta	1.19
52-Week High	$6.17
52-Week Low	$1.08

Volume Today	209.96K
Avg Daily Volume (30D)	332.77K
Relative Volume	0.63x
Volatility (10D)	54.65
Volatility (30D)	69.81
Free Float	96.40%

Analyst Consensus

BUY

Current Price $1.56

Mean Target $7.17

52W Low$1.08 52W High$6.17

Current

Target

$1.08 $6.17

Current Analyst target

+359.40% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0029H8ZG5

ISINUS01438T1060

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.